Brought to you by:
Powered by wagescape.com
Labor Market Pulse
Charlotte-Gastonia-Concord, NC-SC Metro Edition
Focus: LIFE SCI
Charlotte's regulatory pay surge outpaces a cooling metro market.
3.7%
Metro unemployment rate
vs 4.1% national, 11th among large metros
$117,917
Regulatory Affairs pay, metro vs. national
vs $104,000 national, up significantly locally
-11,600 jobs
NC manufacturing payroll change
Jan 2025 to Jan 2026, statewide
34,800+
Life sciences manufacturing employment, NC
Up from zero in 1974; expansion continuing
This Month's Takeaways
Charlotte regulatory pay has pulled ahead of the national market.
Regulatory Affairs Specialist advertised pay rose significantly to $117,917 locally versus a stable $104,000 nationally, consistent with the NC Life Sciences Organization's September forum flagging regulatory and specialized talent as the binding constraint on expansion. Retention plans built on national benchmarks likely understate what it now takes to hold this talent in-market.
Biomanufacturing growth is outrunning the specialized talent pipeline.
BioWork graduates are filling entry-level operator roles at J&J and Fresenius Kabi for roughly $67,000, but that pipeline does not touch CMC, quality, or regulatory leadership — the roles the NC Life Sciences forum identified as the real workforce gap. Headcount plans tied to Amgen or J&J timelines should separate operator staffing from specialized hiring, which will move on a much slower, more expensive track.
Statewide wage softening has not reached life sciences roles.
NC average weekly wages actually declined 0.3% year-over-year and overall wage growth has slowed from 2022 peaks, yet Biostatistician ($140,364) and Clinical Research Associate ($83,636) advertised pay both rose significantly locally. Compensation strategy should treat life sciences as running on a different cycle than the broader metro labor market, not extrapolate from general wage trend data.
CDMO consolidation is quietly reshaping the outsource calculus.
Kincellis Advanced Therapies' leadership consolidation post-merger, paired with sustained CDMO/CMC capacity investment nationally, suggests contract manufacturing options are maturing faster than internal specialized hiring in cell and gene therapy. Build-vs-outsource reviews for CMC-heavy programs may find the outsourcing path has gotten more credible in just the past two quarters.
Local Labor Conditions
Charlotte metro unemployment held at 3.7% in August, tighter than the national 4.1% but reflecting a hiring pace that cooled to roughly 1,200 jobs per month as manufacturing payrolls statewide shed more than 11,000 positions over the past year. Life sciences stands apart from that softening — Amgen's $1B Holly Springs expansion and J&J's $2B Wilson County biologics campus are adding hundreds of manufacturing jobs even as regional IT and traditional manufacturing retrench, concentrating competition for credentialed talent in a narrow set of biomanufacturing corridors.
Leadership & Talent Implications
Metro-level tightness masks a bifurcated market: entry-level biomanufacturing operators are being supplied at scale through programs like Wilson Community College's BioWork pipeline, while specialized scientific, quality, and regulatory talent remains acutely scarce — advertised pay for Regulatory Affairs Specialists in Charlotte has risen sharply to a median of $117,917, actually outpacing the national figure. Organizations planning headcount around the Amgen and J&J expansions should expect operator-level roles to fill relatively efficiently but should budget longer timelines and premium compensation for CMC, quality, and regulatory leadership; current conditions suggest reviewing build-vs-outsource assumptions for specialized functions where local CDMO capacity (including recent CDMO consolidation activity) may offer faster time-to-capability than internal hiring.
